VA
REGN icon

VestGen Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

VestGen Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-414
Closed -$300K – 1149
2026
Q1 		$300K Sell
414
-1,236
-75% -$946K 0.01% 837
2025
Q4 		$1.27M Buy
+1,650
New +$1.12M 0.05% 314
2025
Q2 		– Sell
-534
Closed -$339K – 606
2025
Q1 		$339K Buy
+534
New +$367K 0.02% 438

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

VestGen Advisors's REGN Position: Q2 2026 in Review

VestGen Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 414 shares — an estimated $300K sold.

VestGen Advisors first reported a position in REGN in Q1 2025 and held it in 3 quarters. The position peaked at $1.27M in Q4 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • VestGen Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • VestGen Advisors sold 414 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $300K.
  • VestGen Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • VestGen Advisors's Regeneron Pharmaceuticals position peaked at $1.27M in Q4 2025.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on VestGen Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.